758 reports of this reaction
2.1% of all BUSULFAN reports
#11 most reported adverse reaction
CHRONIC GRAFT VERSUS HOST DISEASE is the #11 most commonly reported adverse reaction for BUSULFAN, manufactured by Otsuka America Pharmaceutical, Inc.. There are 758 FDA adverse event reports linking BUSULFAN to CHRONIC GRAFT VERSUS HOST DISEASE. This represents approximately 2.1% of all 36,413 adverse event reports for this drug.
Patients taking BUSULFAN who experience chronic graft versus host disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CHRONIC GRAFT VERSUS HOST DISEASE is a less commonly reported adverse event for BUSULFAN, but still significant enough to appear in the safety profile.
In addition to chronic graft versus host disease, the following adverse reactions have been reported for BUSULFAN:
CHRONIC GRAFT VERSUS HOST DISEASE has been reported as an adverse event in 758 FDA reports for BUSULFAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
CHRONIC GRAFT VERSUS HOST DISEASE accounts for approximately 2.1% of all adverse event reports for BUSULFAN, making it a notable side effect.
If you experience chronic graft versus host disease while taking BUSULFAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.